Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
出版年份 2014 全文链接
标题
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
作者
关键词
-
出版物
CANCER SCIENCE
Volume 105, Issue 3, Pages 347-353
出版商
Wiley
发表日期
2014-01-10
DOI
10.1111/cas.12350
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials
- (2012) Roberto Iacovelli et al. ACTA ONCOLOGICA
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
- (2012) B. Markman et al. ANNALS OF ONCOLOGY
- Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines
- (2012) Annett Mueller et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo
- (2012) Hui Ren et al. CANCER LETTERS
- Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
- (2012) A.M. Gonzalez-Angulo et al. CANCER TREATMENT REVIEWS
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors
- (2012) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor
- (2012) Patrizia Nanni et al. PLoS One
- Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus
- (2011) Jose Pablo Maroto et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study
- (2011) Neal E. Ready et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
- (2011) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
- (2010) Dorothy A. White et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- (2010) C. O'Brien et al. CLINICAL CANCER RESEARCH
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
- (2009) J.-C. Soria et al. ANNALS OF ONCOLOGY
- Induction of Akt Activity by Chemotherapy Confers Acquired Resistance
- (2009) Wei-Chien Huang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
- (2008) N. T. Ihle et al. CANCER RESEARCH
- Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
- (2008) M.-C. Crouthamel et al. CLINICAL CANCER RESEARCH
- Critical aspects of the Bayesian approach to phase I cancer trials
- (2008) Beat Neuenschwander et al. STATISTICS IN MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now